A 'polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America.

Bautista, LE; Vera-Cala, LM; Ferrante, D; Herrera, VM; Miranda, JJ; Pichardo, R; Sánchez Abanto, JR; Ferreccio, C; Silva, E; Oróstegui Arenas, M; Chirinos, JA; Medina-Lezama, J; Pérez, CM; Schapochnik, N; Casas, JP; (2013) A 'polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America. Health affairs (Project Hope), 32 (1). pp. 155-64. ISSN 0278-2715 DOI: https://doi.org/10.1377/hlthaff.2011.0948

Full text not available from this repository. (Request a copy)


We evaluated the cost-effectiveness of administering a daily "polypill" consisting of three antihypertensive drugs, a statin, and aspirin to prevent cardiovascular disease among high-risk patients in Latin America. We found that the lifetime risk of cardiovascular disease could be reduced by 15 percent in women and by 21 percent in men if the polypill were used by people with a risk of cardiovascular disease equal to or greater than 15 percent over ten years. Attaining this goal would require treating 26 percent of the population at a cost of $34-$36 per quality-adjusted life-year. Offering the polypill to women at high risk and to men age fifty-five or older would be the best approach and would yield acceptable incremental cost-effectiveness ratios. The polypill would be very cost-effective even in the country with the lowest gross national income in our study. However, policy makers must weigh the value of intervention with the polypill against other interventions, as well as their country's willingness and ability to pay for the intervention.

Item Type: Article
Faculty and Department: Faculty of Epidemiology and Population Health > Dept of Non-Communicable Disease Epidemiology
PubMed ID: 23297283
Web of Science ID: 314026100020
URI: http://researchonline.lshtm.ac.uk/id/eprint/1130053


Download activity - last 12 months
Downloads since deposit
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item